Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06227819 · ClinicalTrials.gov registry record
BVA-200 vs BVA-100 Validation Study
A clinical trial of Heart Failure and Diabetes, sponsored by Daxor Corporation.
- Completed
- Registry status
- 62
- Enrollment target
- 1
- Study location
NCT06227819: Completed study of Heart Failure and Diabetes, sponsored by Daxor Corporation.
NCT06227819 is a study of Heart Failure and Diabetes that has completed, run by Daxor Corporation. The registered enrollment target is 62 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06227819, a study of Heart Failure and Diabetes, has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted at other sites, for the purposes of an FDA medical device submission.
Primary Outcome
Comparison of a sufficient number of indicator-dilution volume measurements between BVA-100 and BVA-200 devices to establish substantial equivalence.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST BVA-200
Study Locations (1)
Tennessee
- Daxor Corporation - Oak Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2023-11-30 |
What the finished NCT06227819 record still lists
NCT06227819 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which BVA-200 is the first listed.
NCT06227819 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06227819 about?
NCT06227819 is a clinical study titled "BVA-200 vs BVA-100 Validation Study". The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted...
What is the current status of trial NCT06227819?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2023-05-23. Estimated completion is 2023-11-30.
What conditions does trial NCT06227819 study?
This clinical trial studies the following conditions: Heart Failure, Diabetes, Anemia, Trauma, Kidney Diseases.
What interventions are being tested in trial NCT06227819?
The interventions under investigation include: BVA-200 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06227819?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06227819 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06227819's enrollment target sits among peer trials
62 252nd of 397 higher than 145 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI